Universitätsklinikum Essen

Understanding metric-related pitfalls in image analysis validation (2024) Reinke A, Tizabi MD, Baumgartner M, Eisenmann M, Heckmann-Nötzel D, Kavur AE, Rädsch T, et al. Journal article Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024) Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al. Journal article Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL (2024) Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, et al. Journal article Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma (2024) Brinker TJ, Chanda T, Hauser K, Hobelsberger S, Bucher TC, Garcia CN, Wies C, et al. Journal article Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients with GM2 Gangliosidosis: Beyond Age of Onset (2024) Kern J, Böhringer J, Timmann D, Trollmann R, Stendel C, Kamm C, Röbl M, et al. Journal article “I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab (2024) Hölsken S, Benthin C, Krefting F, Mühlhaus S, Nestoriuc Y, Schedlowski M, Sondermann W Journal article Discontinuation of Fumaric Acid Esters is Affected by Depressive Symptomatology: A Retrospective Analysis (2024) Krefting F, Hölsken S, Schedlowski M, Sondermann W Journal article [Not Available]. (2024) Berg T, Aehling NF, Bruns T, Welker MW, Weismüller T, Trebicka J, Tacke F, et al. Journal article Further delineation of the SCAF4-associated neurodevelopmental disorder (2024) Schmid CM, Gregor A, Ruiz A, Manso Bazús C, Herman I, Ammouri F, Kotzaeridou U, et al. Journal article High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial (2024) Hommerding O, Bernhardt M, Kreft T, Scherping A, Abbas M, Baretton G, Bräsen JH, et al. Journal article